Choosing a first antidepressant can still feel like a coin toss for many patients with major depressive disorder. Actigraphy for antidepressant selection changes that calculus by adding objective, rest-activity data to the clinical picture. A wrist-worn sensor—now available as a prescription actigraph or a validated consumer smartwatch—captures sleep timing, fragmentation, and daily movement over one to two weeks, producing a readout that can be mapped to the pharmacological profiles of SSRIs and SNRIs. This article is a how-to for reading that readout at the point of care.
Why Sleep-Wake Data, Not Just Patient Recall, Should Inform the Choice
Subjective sleep reports are notoriously unreliable in depression. Patients with hypersomnia underestimate daytime sleep while patients with insomnia overestimate how long it takes to fall asleep. Actigraphy captures the actual pattern: when sleep occurs, how broken it is, and how strongly the patient’s day-to-day rhythm is preserved. These patterns correspond to depression subtypes that have historically guided drug selection—but with actigraphy, they can be seen instead of guessed.
Actigraphy also measures the patient’s real-world behavior, not clinic-room performance. A patient who looks euthymic during a fifteen-minute appointment may spend eleven hours in bed and remain behaviorally inert for most of the day. That information changes the therapeutic target: the drug does not need to lift mood alone; it also needs to restore organized activity.
How SSRIs and SNRIs Differ in Their Sleep-Wake Signatures
SSRIs increase serotonergic tone throughout the brain. Serotonin’s effect on sleep is receptor-dependent and dose-dependent; in broad terms, it suppresses REM sleep and can delay sleep onset in the first weeks of treatment. Many patients experience a mild worsening of sleep maintenance until adaptation occurs.
SNRIs add norepinephrine reuptake inhibition. Norepinephrine is a wakefulness-promoting catecholamine that enhances alertness, motor drive, and sympathetic tone. That is why SNRIs are generally more activating than SSRIs—but also why they carry a higher risk of insomnia, nighttime awakenings, and agitation during initiation. This differential effect is the biological basis for using actigraphy to select between the two classes.
Key Actigraphy Metrics for the SSRI-versus-SNRI Question
Four metrics contain most of the decision-relevant information. They should be interpreted together, not in isolation.
Sleep continuity and efficiency
Sleep efficiency compares total sleep time to the time allotted for sleep. Wake after sleep onset—WASO—measures how much of that time is spent awake. Low efficiency with high WASO indicates a hyperarousal state that a noradrenergic drug could aggravate.
Total sleep time and daytime sleep episodes
A sleep fraction well above the age-adjusted norm, plus frequent daytime naps, points to hypersomnia and psychomotor retardation. This is the profile most likely to require a noradrenergic push.
Mid-sleep time
Mid-sleep time is the midpoint between sleep onset and final awakening, and it estimates circadian phase. An unusually early midpoint suggests early-morning awakening; a late midpoint suggests circadian phase delay. Each pattern carries different dosing and co-intervention implications.
Relative amplitude and interdaily stability
Relative amplitude describes the strength of the day-night contrast in activity; interdaily stability describes the consistency of the rhythm from day to day. A flat, fragmented rhythm tells you that the patient is behaviorally disengaged and unpredictable, which matters when choosing an activating agent and scheduling a follow-up actigraphy window.
Four Actigraphy Patterns and the Medication Class They Support
The following pattern-matching rules are heuristics, not laws. They combine the actigraphy metrics into an SSRI-versus-SNRI decision that is grounded in the patient’s measured sleep-wake biology.
Pattern 1: Insomnia-predominant — low sleep efficiency, high WASO
This pattern reflects hyperarousal. Favor an SSRI, preferably a minimally activating compound such as escitalopram rather than fluoxetine. The noradrenergic effect of an SNRI can reinforce nighttime arousal and fragment sleep further. If an SNRI is still needed for comorbid pain or anxiety, start at the lowest dose and re-check the actigraphy trace after two weeks.
Pattern 2: Hypersomnia-anergy — high total sleep time, low daytime activity
Long sleep episodes and sparse daytime movement describe the hypersomnia-anergy pole of depression. Favor an SNRI, particularly venlafaxine or levomilnacipran, because norepinephrine transmission is wakefulness-promoting and better matched to motor retardation than serotonin alone. Among SSRIs, fluoxetine is the closest activating alternative, but it is a second-line choice for this pattern.
Pattern 3: Circadian phase delay — late mid-sleep, peak activity in the evening
When the sleep midpoint is late and the patient remains active into the night, an SSRI combined with morning bright-light exposure is usually a stronger strategy than an SNRI alone. The serotonergic mechanism influences circadian timing, and the actigraphy phase marker tells you precisely when to dose the medication and the light so that the biological clock can re-anchor.
Pattern 4: Circadian phase advance — early mid-sleep, early-morning awakening
An early midpoint with terminal awakening is a melancholic pattern that often responds to a standard SSRI. An SNRI may be appropriate if daytime anergia dominates, but it should be dosed in the morning and monitored for further truncation of sleep.
A Practical Workflow for the Busy Clinic
To make actigraphy reproducible, build it into the existing intake flow rather than treating it as a research protocol.
- Order seven to fourteen days of actigraphy before starting or switching an antidepressant. A research-grade actigraph is ideal, but a validated consumer wearable can suffice if the raw signal is accessible.
- Export the core metrics: sleep efficiency, WASO, total sleep time, mid-sleep time, relative amplitude, and interdaily stability. Most cloud platforms render these automatically.
- Classify the patient into one of the four patterns above. If the profile is mixed, prioritize the nighttime continuity metric first, then the daytime activity level.
- Show the patient the trace during the shared decision-making visit. A visible delayed phase or fragmented rhythm is often more persuasive than a questionnaire score, and it makes the medication class rationale concrete.
- Repeat a 48-to-72-hour actigraphy window around week two or three of treatment. Early improvement in sleep efficiency or daytime activity predicts a favorable subjective response later; a worsening trace argues for a within-class or cross-class switch.
Limits of the Actigraphy-Guided Approach
Actigraphy is decision support, not an oracle. Several boundaries should keep it in perspective.
- Actigraphy measures movement, not arousal. A still body can be awake; a moving body can be asleep.
- The heuristics are probabilistic. An insomnia-predominant patient can still respond to an SNRI; the patterns shift the odds, not the certainty.
- Caffeine, alcohol, hypnotics, and shift work can obscure the trace. Interpret data only when the recording window is representative of ordinary life.
- Do not treat a hypersomnia pattern as proof of unipolar depression. Screen for bipolar disorder before starting an SSRI or SNRI, as these agents can destabilize a bipolar II patient.
- Consider obstructive sleep apnea when sleep is long yet unrefreshing. Treating apnea may resolve the depressive symptoms without any antidepressant.
Conclusion
Actigraphy will not replace a thorough psychiatric interview, but it can make the first antidepressant choice more intelligent and less sequential. Pairing sleep-wake data with the known neuropharmacology of SSRIs and SNRIs gives clinicians a way to move from trial-and-error toward a targeted initial prescription. For the patient who will spend the next month on that medication, the shift matters.
